<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta content="Studies" property="og:title"/>
    <meta content="website" property="og:type"/>
    <meta content="https://allytoall.github.io/thumbnails/studies.png" property="og:image"/>
    <meta content="https://allytoall.github.io/studies/cpp" property="og:url"/>
    <meta content="A page containing a bunch of studies"
          property="og:description"/>
    <title>Studies</title>
    <link href="/css/output.css" rel="stylesheet">
    <link href="/css/studies.css" rel="stylesheet">
    <script src="/js/urlHandling.js"></script>
    <script src="/js/studyCount.js"></script>
</head>
<body>
<p class="heading">
    Studies on Central Precocious Puberty
</p>
<p id="count">This page contains N studies</p><br>

<h1 id="10.1007/s004310051289">
    Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after
    therapy with gonadotropin-releasing hormone analogues
</h1>
<p>
    <a href="https://doi.org/10.1007/s004310051289">
        https://doi.org/10.1007/s004310051289
    </a>
</p><br>

<h1 id="10.1016/j.mce.2006.04.012">
    Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function
</h1>
<p>
    <a href="https://doi.org/10.1016/j.mce.2006.04.012">
        https://doi.org/10.1016/j.mce.2006.04.012
    </a>
    Depot gonadotropin releasing hormone (GnRH) agonist (GnRHa) therapy is the treatment of choice for patients with
    central precocious puberty (CPP). It is still unclear whether long-term exposure to GnRHa is associated with
    impaired reproductive function in adulthood.
    The present study was performed on 46 women, former CPP patients, 12.5 Â± 3.7 years after the discontinuation of
    treatment with depot GnRHa. In a structured interview, we assessed general health status, clinical signs possibly
    associated with hyperandrogenism, menstrual cycle, gynaecological diseases and reproductive function. It appears
    that long-term treatment with depot GnRHa is safe and does not impair reproductive function. The risk of former CPP
    patients to develop hirsutism and/or polycystic ovary syndrome does not seem to be increased compared to the normal
    population but this issue needs to be addressed in further long-term follow-up studies.
</p><br>

<h1 id="10.1210/jcem-67-2-368">
    Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious
    puberty
</h1>
<p>
    <a href="https://doi.org/10.1210/jcem-67-2-368">
        https://doi.org/10.1210/jcem-67-2-368
    </a>
</p><br>

<a href="/studies">
    <button class="btn gray">
        Return to studies
    </button>
</a>

<a href="/">
    <button class="btn gray">
        Return to home
    </button>
</a>
</body>
</html>